Difluprednate for the prevention of ocular inflammation postsurgery: an update
Eric D DonnenfeldOphthalmic Consultants of Long Island, Rockville Centre, NY, USAPurpose: To review the most recent published data regarding the novel potent steroid, difluprednate ophthalmic emulsion, 0.05%.Methods: A comprehensive search of recent published literature including difluprednate was p...
Guardado en:
Autor principal: | Donnenfeld ED |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9c1dd1b86ea2459cb5eb4d312bda50c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Stephen Smith, et al.
Publicado: (2010) -
The role of difluprednate ophthalmic emulsion in clinical practice
por: Karim N Jamal, et al.
Publicado: (2009) -
Topical difluprednate for the treatment of Harada’s disease
por: Onishi SM, et al.
Publicado: (2015) -
Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
por: Carreño E, et al.
Publicado: (2012) -
Interferons and their potential in the treatment of ocular inflammation
por: Friederike Mackensen, et al.
Publicado: (2009)